Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. 2009

Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
Department of Urology, Chang Gung Memorial Hospital Kaohsiung, Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China. chuang82@ms26.hinet.net

OBJECTIVE We evaluated the safety and efficacy of intravesical liposomes, a mucosal protective agent, compared to oral pentosan polysulfate sodium for interstitial cystitis/painful bladder syndrome. METHODS We performed a prospective longitudinal study of the effect of 2 independent treatments (intravesical liposomes and oral pentosan polysulfate sodium) in patients with interstitial cystitis/painful bladder syndrome. Ten possible responses (or measures) to treatment were monitored at 3 time points, including baseline, and weeks 4 and 8. A total of 24 patients with interstitial cystitis/painful bladder syndrome were evaluated in a 1:1 ratio to intravesical liposomes (80 mg/40 cc distilled water) once weekly or to oral pentosan polysulfate sodium (100 mg) 3 times daily for 4 weeks each. RESULTS No patient had urinary incontinence, retention or infection due to liposome instillation. There were no unanticipated adverse events and no significant worsening of symptoms during followup. Statistically significant decreases in urinary frequency and nocturia were observed in each treatment group. Statistically significant decreases in pain, urgency and the O'Leary-Sant symptom score were observed in the liposome group. Decreased urgency in the liposome group had the most profound effect of the ordinal measures. CONCLUSIONS Each glycosaminoglycan directed treatment seemed beneficial. Liposome intravesical instillation is safe for interstitial cystitis/painful bladder syndrome with potential improvement after 1 course of therapy for up to 8 weeks. Intravesical liposomes achieved efficacy similar to that of oral pentosan polysulfate sodium. Further large-scale placebo controlled studies are needed. Intravesical liposomes appear to be a promising new treatment for interstitial cystitis/painful bladder syndrome.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010426 Pentosan Sulfuric Polyester A sulfated pentosyl polysaccharide with heparin-like properties. Pentosan Polysulfate,Polypentose Sulfate,BAY-946,Elmiron,Fibrocid,HOE-946,HOE-BAY 946,HOE-BAY-946,Hemoclar,PZ-68,PZ68,Pentosan Polysulfate Sodium,Pentosan Polysulphate Sodium,Pentosane Sulfuric Polyester,Polysulfated Xylan,SP-54,Tavan SP 54,Xylan SP54,Xylan Sulfate,BAY 946,HOE 946,HOE BAY 946,PZ 68,Polyester, Pentosan Sulfuric,Polyester, Pentosane Sulfuric,Polysulfate Sodium, Pentosan,Polysulfate, Pentosan,Polysulphate Sodium, Pentosan,SP 54,SP 54, Tavan,SP54,SP54, Xylan,Sodium, Pentosan Polysulfate,Sodium, Pentosan Polysulphate,Sulfate, Polypentose,Sulfate, Xylan,Sulfuric Polyester, Pentosan,Sulfuric Polyester, Pentosane,Xylan, Polysulfated
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000283 Administration, Intravesical The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. Bladder Drug Administration,Drug Administration, Bladder,Instillation, Bladder,Intravesical Drug Administration,Administration, Intravesical Drug,Injections, Intravesical,Intravesical Administration,Intravesical Injection,Intravesical Instillation,Administration, Bladder Drug,Administrations, Bladder Drug,Administrations, Intravesical,Administrations, Intravesical Drug,Bladder Drug Administrations,Bladder Instillation,Bladder Instillations,Drug Administration, Intravesical,Drug Administrations, Bladder,Drug Administrations, Intravesical,Injection, Intravesical,Instillation, Intravesical,Instillations, Bladder,Instillations, Intravesical,Intravesical Administrations,Intravesical Drug Administrations,Intravesical Injections,Intravesical Instillations
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D018856 Cystitis, Interstitial A condition with recurring discomfort or pain in the URINARY BLADDER and the surrounding pelvic region without an identifiable disease. Severity of pain in interstitial cystitis varies greatly and often is accompanied by increased urination frequency and urgency. Cystitis, Chronic Interstitial,Interstitial Cystitis,Bladder Pain Syndrome,Chronic Interstitial Cystitis,Interstitial Cystitis, Chronic,Painful Bladder Syndrome,Bladder Pain Syndromes,Chronic Interstitial Cystitides,Cystitides, Chronic Interstitial,Cystitides, Interstitial,Interstitial Cystitides,Interstitial Cystitides, Chronic,Pain Syndrome, Bladder

Related Publications

Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
January 2014, American journal of clinical and experimental urology,
Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
December 2021, Aktuelle Urologie,
Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
October 2007, The Cochrane database of systematic reviews,
Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
November 2013, Hospital pharmacy,
Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
January 2014, ISRN pharmacology,
Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
October 2015, The Ulster medical journal,
Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
January 2023, Bladder (San Francisco, Calif.),
Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
April 1999, Urology,
Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
January 2012, Lower urinary tract symptoms,
Yao-Chi Chuang, and Wei-Chiang Lee, and Wei-Chia Lee, and Po-Hui Chiang
April 2017, International urogynecology journal,
Copied contents to your clipboard!